In prostate cancer, androgen blockade strategies are commonly used to treat osteoblastic
bone metastases. However, responses to these therapies are typically brief, and the …

Prostate cancer is the most common malignancy of men in Western countries. Patients with
advanced prostate cancer suffer from incurable bone metastases. Recent data indicate that …

Prostate cancer is the most common cancer in US men and the second leading cause of
cancer deaths. Fibroblast growth factor 23 (FGF23) is an endocrine FGF, normally …

Abstract Fibroblast growth factor 8 (FGF8) has been shown to play a key role in prostate
carcinogenesis. It was initially cloned as an androgen induced protein in mouse mammary …

Bone is the most frequent site of prostate cancer (PCa) metastasis; however, little is known
about the role of the most common cell in bone, the osteocyte (OCy), in cancer biology. In …

Enhanced mesenchymal expression of FGF10 led to the formation of multifocal PIN or
prostate cancer. Inhibition of epithelial FGFR1 signaling using DN FGFR1 led to reversal of …

BACKGROUND Alterations in fibroblast growth factors (FGFs) production and/or FGF
receptors expression have been described to play key roles in prostate tumor progression …

Identification of prostate cancers at high risk of progression is difficult and a better
understanding of how peptide growth factors influence cellular function might be useful …

Bone metastases occur in patients with advanced-stage prostate cancer (PCa). The cell-cell
interaction between PCa and the bone microenvironment forms a vicious cycle that …

Survival and capability of cancer cells to form metastases fundamentally depend on
interactions with their microenvironment. Secondary tumors originating from prostate …